Entropy Neurodynamics Limited
Entropy Neurodynamics Limited
Your view on ENP.AX
Overview
What the company does, where it operates, and who runs it.
About Entropy Neurodynamics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jason Alan Carroll
- Headquarters
- 697 Burke Road, Camberwell, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jason Alan Carroll
- Headquarters
- 697 Burke Road, Camberwell, VIC, AU
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States.
The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness.
Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome.
Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Entropy Neurodynamics Limited. Starting points for Entropy Neurodynamics Limited: beta -0.36 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Entropy Neurodynamics Limited. Entropy Neurodynamics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Entropy Neurodynamics Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Entropy Neurodynamics Limited. Entropy Neurodynamics Limited has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ORKAOruka Therapeutics, Inc. | Healthcare | NASDAQ | $6.5B | ||
| ORMPOramed Pharmaceuticals Inc. | Healthcare | NASDAQ | $155.2M | ||
| ORPOFOSE Immunotherapeutics S.A. | Healthcare | OTC | $260.3M | ||
| ORYZFOryzon Genomics S.A. | Healthcare | OTC | $283.9M | ||
| OSRHWOSR Holdings, Inc. | Healthcare | NASDAQ | $7.8M | ||
| OSTXOS Therapies Incorporated | Healthcare | AMEX | $42.0M | ||
| OTLCOncotelic Therapeutics, Inc. | Healthcare | OTC | $21.2M | ||
| OTLKOutlook Therapeutics, Inc. | Healthcare | NASDAQ | $94.9M | ||
| OVIDOvid Therapeutics Inc. | Healthcare | NASDAQ | $415.2M | ||
| OXBOFOxford BioDynamics Plc | Healthcare | OTC | $4.3M | ||
| OZYMFStrategic Partners A/S | Healthcare | OTC | $3.7M | ||
| PAB.AXPatrys Limited | Healthcare | ASX | — | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Entropy Neurodynamics Limited. Coverage tracks Entropy Neurodynamics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Entropy Neurodynamics Limited.